Post hoc analysis of tumor tissue from the Stupp trial found that patients whose tumors exhibited methylation of the MGMT promoter region experienced improved survival compared with patients whose tumors lacked MGMT methylation, and derived significant additional survival benefit from the addition of TMZ. The gene discussed is MGMT; the disease is neoplasm.